Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development

Graphical Abstract

Highlights

- CAP256 V2 apex bnAbs affinity mature with sialic acid (SIA)-bearing HIV Env glycans
- Both germline and somatic-mutated HC-Ab residues contribute to SIA recognition
- SIA-specific maturation pattern is conserved in two genetically related bnAb lineages
- SIA-specific affinity maturation counters virus escape and helps bnAb development

Authors
Raiees Andrabi, Ching-Yao Su, Chi-Hui Liang, ..., Chung-Yi Wu, Chi-Huey Wong, Dennis R. Burton

Correspondence
burton@scripps.edu

In Brief
Understanding the molecular basis for the development of HIV Env-specific bnAbs is key for vaccine design. Andrabi et al. find that CAP256 V2 apex lineage Abs affinity mature with sialic acid containing complex-type glycans on HIV envelope trimer. This glycan recognition enables the development into bnAbs by resisting virus escape.
Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development

Raiees Andradi, 1,2,3,6 Ching-Yao Su, 1,2,3,6 Chi-Hui Liang, 1,2,3 Sachin S. Shivatate, 4 Bryan Briney, 1,2,3 James E. Voss, 1,2,3 Salar Khan Nawazi, 1,2 Chung-Yi Wu, 4 Chi-Huey Wong, 4 and Dennis R. Burton 1,2,3,5,7*  

1Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA  
2International AIDS Vaccine Initiative, Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA  
3Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA  
4Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan  
5Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA 02114, USA  
6These authors contributed equally  
7Lead contact  
*Correspondence: burton@scripps.edu  
http://dx.doi.org/10.1016/j.immuni.2017.08.006

SUMMARY

Apex broadly neutralizing HIV antibodies (bnAbs) recognize glycans and protein surface close to the 3-fold axis of the envelope (Env) trimer and are among the most potent and broad Abs described. The evolution of apex bnAbs from one donor (CAP256) has been studied in detail and many Abs at different stages of maturation have been described. Using diverse engineering tools, we investigated the involvement of glycan recognition in the development of the CAP256.VRC26 Ab lineage. We found that sialic acid-bearing glycans were recognized by germline-encoded and somatically mutated residues on the Ab heavy chain. This recognition provided an “anchor” for the Abs as the core protein epitope varies, prevented complete neutralization escape, and eventually led to broadening of the response. These findings illustrate how glycan-specific maturation enables a human Ab to cope with pathogen escape mechanisms and will aid in optimization of immunization strategies to induce V2 apex bnAb responses.

INTRODUCTION

A promising track for HIV vaccine design is to take lessons from broadly neutralizing antibodies (bnAbs) and their interaction with Envelope trimer (Env) to craft potential immunogens in an approach described as “Reverse Vaccinology 2.0” (Burton, 2002; Rappuoli et al., 2016). It has become apparent that multiple immunogens will likely be required to guide the antibody response from their unmutated ancestors to bnAbs (Briney et al., 2016a; Dosenovic et al., 2015; Escolano et al., 2016; Jardine et al., 2015; Tian et al., 2016), including immunogens to trigger unmutated precursor B cells, to shepherd them along favorable pathways, and to maximize their interaction with a broad spectrum of native Env molecules (Andradi et al., 2015; Bhiman et al., 2015; Dimitrov, 2010; Doria-Rose et al., 2014; Gorman et al., 2016; Jardine et al., 2013; Liao et al., 2013; McGuire et al., 2016; Steichen et al., 2016; Xiao et al., 2009). One of the targets of bnAbs that has attracted a great deal of attention is the V2 apex region of Env (Andradi et al., 2015; Bhiman et al., 2015; Doria-Rose et al., 2014; Sok et al., 2014; Walker et al., 2009, 2011). bnAbs to this region are induced in a substantial proportion of the individuals who make such Abs (Georgiev et al., 2013; Landais et al., 2016; Walker et al., 2010) and the V2 apex response tends to appear earlier in natural HIV infection than other bnAb responses (Doria-Rose et al., 2014; Wibmer et al., 2013), both factors that favor it as a vaccine target.

The V2 apex represents a complex antigenic region. Broadly, a lysine-rich set of residues on V2 come together in space around the 3-fold axis at the “top” of the spike to constitute a basic region that is recognized by acidic residues (aspartate and sulfated tyrosines) at the tip of a long HCDR3 (heavy chain complementarity-determining region 3 of the heavy chain) of the bnAb. In order to access the basic region, the HCDR3, and to some extent the other CDRs, of the bnAb must penetrate the glycan shield of Env and particularly interact with and/or accommodate a conserved glycan at N160 and, to a lesser extent, a second nearby glycan at N156 or rarely N173 (Amin et al., 2013; Gorman et al., 2016; Lee et al., 2017; McLellan et al., 2011; Pancera et al., 2013; Walker et al., 2009). Detailed studies have combined structure, nuclear magnetic resonance (NMR), and mutagenesis analyses to characterize glycan recognition by the V2 apex bnAbs PG9 and PG16 (McLellan et al., 2011; Pancera et al., 2013). These studies identified PG9 and PG16 as interacting with a Man9GlcNAc2 structure at N160 and a sialic acid containing hybrid-type glycan at N173 or N156. The studies employed V1V2 loops on scaffolds rather than native Env and this remains a caveat to this analysis. Particular focus was placed on a terminal sialic acid on the glycan at N173 or N156 interacting with a tripeptide (RSH) motif in the light chain of PG16.

The molecular information provided by these studies is extremely valuable but more insight is needed prior to embarking upon a systematic multistage vaccine effort to target the V2 apex region. One approach is to compare different V2 apex bnAbs and
identify common features that could be important in considering immunogen design. This approach has been valuable in identifying potential V2 apex bnAb precursor-targeting immunogens (Andrabi et al., 2015; Gorman et al., 2016; Sanders et al., 2015) that are currently under study. Four prototype V2 apex bnAb lineages have been described and two of them, PG9 and CAP256-VRC26, are derived from variable heavy chain (VH) gene segments that show 99% sequence identity and use the same D-gene that provides critical anionic residues for protein epitope recognition (Andrabi et al., 2015; Bonsignori et al., 2011; Doria-Rose et al., 2014; Walker et al., 2009, 2011). A second approach is to investigate the co-evolution of bnAb and virus during natural infection to identify critical stages in the maturation of the response and attempt to extract information that can aid in immunogen design (Doria-Rose et al., 2014; Liao et al., 2013; MacLeod et al., 2016). The CAP256 lineage (referred to as CAP256.01-33) has been extensively studied and first appeared after superinfection of the donor. This lineage has a particularly long HCDR3, which is 35 amino acids (Kabat numbering convention) in the unmutated common ancestor (UCA) and increases by insertions to 37 amino acids in the most potent mature bnAbs (Doria-Rose et al., 2014, 2015). One detailed study of co-evolution in the CAP256 lineage showed different fates for Abs originating in the UCA. One track led to “dead-end” Abs that did not evolve as they could not respond to viral diversity. A second track continued to evolve, resulting in highly somatically mutated Abs, some that were able to neutralize many viral variants as well as “off-track” Abs that were limited in their neutralization breadth (Bhiman et al., 2015).

Here, we sought to take advantage of the availability of Abs from the CAP256 lineage to study the role of glycan interactions in the evolution of the lineage. We compared a number of features of the interactions of CAP256 Abs with glycans and investigated the role of glycan recognition in resisting neutralization escape. We concluded that recognition of sialic acid-bearing glycans was critical in the evolution of CAP256 family antibodies and depended upon germline-encoded and somatically mutated residues in CDRH2, and that acquisition of these somatic mutations early in Ab maturation could help anchor Abs to their epitope even in the face of mutations in the core protein part of the epitope.

RESULTS

CAP256 Lineage Abs Evolve in Terms of Glycan Recognition during Affinity Maturation with Possible Contribution from Terminal Sialic Acids

The four V2 apex bnAb prototype lineages—PG9, CH01, PGT145, and CAP256.09—typically depend on glycans at positions N160 and N156, or less often N173 (McLellan et al., 2011; Pancera et al., 2013; Walker et al., 2009), for neutralization and binding to the Env trimer. The N173 glycan site is relatively close to the N156 site and it appears that the N173 glycan can act to replace the N156 glycan in the context of certain isolates in the binding of V2 apex bnAbs (McLellan et al., 2011; Pancera et al., 2013). The first three Ab prototypes show an absolute dependence on the N160 glycan site for neutralization whereas the dependence is variable with respect to glycan N156 or N173. In contrast, the neutralizing activity of the CAP256.09 Ab prototype is partially dependent on both N156 or N173 and N160 glycans in an isolate- and context-dependent manner (Doria-Rose et al., 2014, 2015).

To assess the dependency of CAP256 lineage Abs during maturation on Env glycans and glycan character in detail, we employed three approaches. We carried out our studies in the context of the CRF250 isolate trimer as this isolate binds to inferred-unmutated ancestor versions of multiple V2 apex bnAb prototypes and represents a potential B cell precursor targeting immunogen (Andrabi et al., 2015).

First, we generated CRF250Env virus variants that lacked glycans at positions N156 and N160 and investigated neutralization by CAP256 lineage members (Figures 1A, 1B, and S1). The wild-type (WT) CRF250 virus grown in 293T cells was neutralized by all CAP256 Ab lineage members, with the exception of Ab CAP256.20. This pattern was similar to that seen for the CAP256 superinfecting virus (CAP256.SU), highlighting the antigenic resemblance of CRF250 Env and the CAP256.SU Env, which, or a close descendant thereof, is believed to have led to initiation of the CAP256 Ab lineage (Figures 1B and S1; Bhiman et al., 2015; Doria-Rose et al., 2015). Both N156 and N160 glycan-eliminated variants were less well neutralized by CAP256 bnAbs, the effect being more prominent with N156 glycan elimination (N156A: 82-fold drop) than N160 glycan removal (N160A; 80-fold drop in average IC50 compared to the WT CRF250 virus) (Figures 1B and S1). Effects were seen throughout the lineage although the most potent neutralizing Abs to CRF250, CAP256.03 and .25, tolerated the loss of the N160 glycan very well (Figure S1).

As a second approach to glycan dependence of Ab binding, we modified the glycan composition on the CRF250 Env trimer by growing virus in the presence of the glycosidase inhibitors kifunensine (ER α-mannosidase I inhibitor) and swainsonine (GolgI α-mannosidase II inhibitor) and in 293S cells, which lack an N-acetyl glucosaminyl transferase enzyme. Kifunensine-treated cells were expected to yield viruses with mostly high-mannose (Manα9GlcNAc2) glycans; swainsonine-treated cells to yield viruses with high-mannose or hybrid-type glycans with a Manα9GlcNAc2 glycan core and a branch that may potentially terminate in a sialic acid (Doores and Burton, 2010; Pancera et al., 2013); and 293S cell-grown viruses to have Manα9GlcNAc2 glycans without any hybrid or complex-type glycan character. Neutralization sensitivity was substantially reduced by kifunensine treatment (a 58-fold increase in average IC50 titers), implying that binding of CAP256 Abs was disfavored by high-mannose-only glycans (Manα9GlcNAc2) at one or both of the N156 and N160 positions. In contrast, neutralization sensitivity was increased by swainsonine treatment as compared to the WT CRF250 virus, suggesting a preference for hybrid glycans at either position. The 293S cell-treated virus overall showed a decrease in neutralization compared to 293ST-WT virus (a 28-fold drop in average IC50 titers); however, this drop in IC50 titers appeared to be mainly contributed by the later Ab lineage members (Figures 1B and S1). This latter observation was again consistent with an apparent preference for hybrid glycans, especially as the lineage progresses.

To gain insight into the glycans recognized at the N156 and N160 positions by the CAP256 bnAbs, we combined the CRF250 Env glycan eliminations at N156 and N160 with glycan-modifying
reagents to produce homogeneous virus glycovariants. One caveat of this analysis was that the modifications could affect glycan processing that may, in turn, influence protein folding in the V2 apex region and thus Ab accessibility to the region. Nevertheless, we considered it useful to study the effects of modifications on one glycan in the absence of the other. We observed an increase in neutralization sensitivity to the CAP256 bnAbs, when the CRF250 N156A virus was produced in the presence of kifunensine while swainsonine treatment had little to no effect (Figures S1A and S1D). These results suggest that the CAP256 bnAbs prefer high-mannose glycans (Man8-9GlcNAc2) at the N160 glycan position but that the native sugar at this position seems to include some proportion of hybrid or complex-type. In contrast, the CRF250 N160A virus with kifunensine had an overall opposite effect on neutralization sensitivity (Figures S1A and S1E), suggesting that a smaller high mannose or one with hybrid or complex glycan character may be preferred at the N156 position. Again, the above caveat should be noted.

Figure 1. CAP256 Lineage Abs Show Varying Glycan Specificity and Sialic Acid Reactivity as Measured by Neutralization, Glycan Array, and Env Trimer Binding

(A) A phylogenetic tree based on the variable heavy (VH) chain region of CAP256 lineage monoclonal antibodies (CAP256.01-32, I1, and I2). The tree originates from the VH3-30*18 germline gene present in CAP256 UCA. The Abs are colored based on time of sampling (wpi: weeks post infection).

(B) Heatmap representation of the IC50 neutralization titers of the CAP256 Abs with CRF250 wild-type virus (293T). Fold changes in the IC50 neutralization titers of the CAP256 Abs for CRF250 glycan eliminated variants at positions N156 (N156A) and N160 (N160A) and viral glycovariants produced in presence of glycosidase inhibitors (kifunensine [Kif] and swainsonine [Swain]) or in a 293S cell line, which lacks an N-acetyl glucosaminyl transferase enzyme. The mAbs were tested in a TZM-bl cell based infectivity assay (Ab concentration range: IC50 < 0.00001 or > 10 μg/mL) and the neutralization IC50 fold changes are represented in heatmap format as indicated in the key. An IC50 fold change value of 1.0 indicates that IC50 neutralization titer is unchanged between the WT virus (293T) and the virus variant.

(C) Reactivity of the CAP256 Abs to glycans on glycan microarrays. Binding is represented as average fluorescence intensity (a.u.) with error bars showing standard deviation from the mean. The symbols for each monosaccharide are indicated.

(D) Octet binding response of the CAP256 Abs to CRF250 WT trimer and its three desialylated forms (α2,3 or α2,6 alone or α2,3,6,8,9 cocktail sialidase-treated trimers). The mAbs were immobilized onto an anti-human IgG-Fc sensor followed by dipping these biosensors into the trimer solution and the Ab-trimer interaction is represented as binding curves showing the association (120 s; 180–300) and dissociation (240 s; 300–540).

See also Figures S1A and S2.
As a third approach to glycan dependence of Ab binding, we tested CAP256 mAbs binding to a variety of human glycans on glycan microarrays. This approach revealed a strong binding of some of the more mature CAP256 Ab lineage members to bi-, tri-, and tetra-antennary glycans with 2,6-linked sialic acid residue as a terminal sugar (Figures 1C, S2A, and S2B). As for the CAP256 Ab members here, V3-glycan PGT121 bnAb lineage members have been previously shown to bind complex-type glycans terminating with 2,6-linked sialic acid residues (Mouquet et al., 2012). The early CAP256 Ab members showed no detectable interaction—this does not mean that there is no contact of these early Abs with sialic acid. Indeed, data presented in the next section suggested there is contact. However, such contact must presumably involve a weaker interaction. A failure to detect glycan binding on arrays despite interaction being shown between Ab and glycan on a native Env structure has been previously described (Julien et al., 2013).

To specifically probe the importance of sialic acid recognition by the CAP256 Ab lineage on the native Env trimer, we investigated the effects of sialidase treatment of CRF250 SOSIP trimer on the binding of CAP256 Abs by Bio-Layer Interferometry (BLI) or Octet. We treated the CRF250 SOSIP.664 trimer with 2,3- or 2,6-sialidases alone or with a cocktail of 2,3-, 2,6-, 2,8-, and 2,9-sialidases to remove terminal sialic acid-specific glycosidic linkages. We assessed the binding of the CAP256 Ab lineage members to the WT CRF250 trimer and its three desialylated forms. Octet revealed that the binding of CAP256 Abs to 2,3-sialidase-treated CRF250 trimer remained mostly uniform throughout the lineage and only a small fraction of Abs showed small changes in binding to the 2,3-desialylated protein as compared to the WT trimer (Figures 1D and S2C). However, for 2,6-sialidase-treated trimer, a number of later mature Abs showed a trend for somewhat weaker binding as compared to WT trimer, consistent with array data (Figures 1D and S2C). The effect was most pronounced for the CAP256.21 mAb. In contrast to the later Abs, the earlier Abs did not show any noticeable 2,6-sialidase effects in line with their lack of binding to arrays expressing 2,6-sialic acid.

Overall, the findings suggest that the CAP256 lineage Abs have evolved in terms of glycan recognition during affinity maturation and there is an indication that binding of terminal sialic acids contributes.

**Critical CAP256 Antibody Residues for Sialic Acid Recognition Are Located in the CDRH2**

To better understand how sialic acid recognition evolves during CAP256 Ab lineage development, we sought to identify the most critical CAP256 Ab residues for glycan recognition and investigate how these residues were maintained or evolved during maturation of the response. We focused on the heavy chain (HC) of the CAP256 Abs since this chain dominates the activity of these Abs. Analysis of the HC sequences revealed nine amino acid positions, including four positions in CDRH2 and five positions in CDRH3, that could potentially differentiate glycan-reactive Ab sub-lineage members from non-reactive ones (Figure S3A). We chose CAP256.09 as a prototype Ab from the glycan-reactive Ab sub-lineage and generated single amino acid substitutions at the above nine positions in the HC. The WT Ab and its variants were tested for neutralizing activity against CRF250 virus and for binding to soluble CRF250 and BG505 SOSIP.664 trimers by Octet (Figure S3B). With the exception of K100S-A Ab variant, whose neutralizing activity with CRF250 virus was slightly enhanced, the neutralizing and binding activities of all the CAP256.09 Ab variants was reduced substantially as compared to the WT Ab, indicating that the substituted residues contribute to neutralization and trimer binding.

To specifically identify residues in the HC most critical for glycan recognition, we first assessed the binding of CAP256.09 WT Ab and nine variants to glycans on a microarray. The WT Ab reacted strongly to 2,6-linked sialic acid residue-containing glycans while the CDRH2 variants (D53A, K57A, H59A, and W64A) Ab variants, in addition to a single CDRH3 variant (A100X-G), lost binding to the these glycans (Figure 2A). A similar glycan binding pattern was observed for a more potent CAP256 Ab lineage member, CAP256.25, and its corresponding CDRH2 Ab variants (Figure 2B), thus suggesting a role for these germline and somatically mutated residues in recognition of 2,6-linked sialic acid on glycans.

Previously, we showed that the VH-germline gene families of the CAP256 and PG9 or PG16 Ab lineages share amino acid sequence similarities (Andrabi et al., 2015). Analysis of the mature VH-gene of the CAP256 and PG9 Ab lineages revealed a common maturation pattern in the CDRH2 residues of the two lineages (Y59 to H and K64 to W) (Figure 2C). The data suggest that this pattern may be associated with the critical nature of these residues for glycan recognition. Indeed, functional analysis of the CDRH2 substitutions in the context of PG9 and PG16 bnAbs showed a similar dependence on the glycans as CAP256 Ab lineage members (Figures S3C–S3F). Examination of the crystal structure of PG9 and CAP256.09 bnAb prototypes shows that the four residues discussed above are close to each other and form a cage-like structure with K57 and H59 residues at the center (Figure 2D).

Overall, therefore, we observed two genetically related Ab lineages following a conserved affinity maturation pattern that helps them to recognize sialic acid-containing glycans on HIV Env trimer.

**Both Germline and Somatically Mutated CAP256 CDRH2 Residues Contribute to Env Binding and Neutralization but the Latter Are Most Important**

We next sought to assess how the CDRH2 germline and somatically mutated residues identified above contributed to V2 apex bnAb binding to Env and neutralization, in particular in the context of the critical glycans at N160 and N156. Previously, a number of structural and analytical studies have argued the presence of both high-mannose and complex-type glycans at glycan positions N160 and N156 (or occasionally N173) on diverse isolates (Amin et al., 2013; Behrens et al., 2016; Gristick et al., 2016; McLellan et al., 2011; Pancera et al., 2013). Further, structural studies have shown that PG9 and PG16 Abs make contact with N160 and N156 or N173 glycans on Env V2 scaffolds through both germline and somatically mutated residues (McLellan et al., 2011; Pancera et al., 2013).

To investigate, we generated a series of N156 or N173 and N160 glycan-eliminated variants on a panel of diverse env backgrounds. We tested these viruses and the glycan mutants in neutralization against two WT V2 apex bnAbs, PG16 and
For PG16 Ab and its Ab variants, neutralization was invariably completely eliminated on all N160 glycan-removed env mutants. This feature rendered it impossible to separate effects of the CDRH2 substitutions on N160 and N156 or N173 glycan interaction. However, CAP256 Ab lineage member retained some activity in many cases in N160- and N156- or N173-eliminated mutations, allowing the corresponding glycan-deficient viruses to be used to explore the behavior of the glycans individually as described earlier, although now in the context of the contribution of the CDRH2 substitutions to binding to each glycan. Again, we note the caveat that the loss of one glycan may impact the processing of the other.

Focusing on WT CAP256 Ab lineage member, CAP256.25, whose neutralizing activity was previously shown to be less affected by eliminating glycans (Doria-Rose et al., 2015), we noted a dependence of neutralization on the glycans N156 and N160 in an isolate- and context-specific manner, the loss of neutralizing activity being more common for the N160 glycan elimination, i.e., when N156 was the remaining glycan (Figure 3A).

Considering next neutralization of the WT viruses by the two germline CDRH2 Ab variants (D53A and K57A), we showed limited reduction (up to 18-fold) in the neutralizing activities as compared to the WT CAP256.25 Ab. However, substitutions involving two of the CDRH2 somatic mutations (H59A and W64A), the WT virus-neutralizing activities of the Ab variants were significantly reduced with the effect being generally more pronounced for the W64 residue substitution (>1,000-fold IC₅₀ change) (Figure 3A). Focusing then on the CDRH2 variant Abs (D53A and K57A) neutralizing the N160A and N156A viruses,
**Figure 3. Neutralization of a Panel of Viruses and Glycovariant Viruses Suggests that CAP256.25 Ab CDRH2 Residues Interact with Sialic Acid Likely on N156 Glycan**

(A) Neutralization of a panel of viruses including N156 or 173A and N160A variants by CAP256.25 and PG16 Abs and their CDRH2 variants. Neutralization heatmaps based on the IC$_{50}$ titers show the effect of glycan removals on antibody neutralizing activity. PGT128 (an N332-V3 Ab) and PGT151 (a gp120-41 interface Ab) were used as controls.

(B) Neutralization titration of CAP256.25 WT Ab and its CDRH2 substituted variants against two representative viruses, CAP45_G3 and Du156.12, and their glycan-eliminated N156A, N160A variants.

<table>
<thead>
<tr>
<th>Virus</th>
<th>N156/173</th>
<th>N160</th>
<th>CAP256.25</th>
<th>PG16</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRF250</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>-</td>
<td>0.00001</td>
<td>0.001</td>
</tr>
<tr>
<td>N156A</td>
<td>+</td>
<td>+</td>
<td>0.0003</td>
<td>0.003</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>+</td>
<td>0.0004</td>
<td>0.006</td>
</tr>
<tr>
<td>BG505_C2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.0002</td>
<td>0.001</td>
</tr>
<tr>
<td>N156K</td>
<td>-</td>
<td>+</td>
<td>0.2</td>
<td>0.06</td>
</tr>
<tr>
<td>N160K</td>
<td>+</td>
<td>-</td>
<td>8.6</td>
<td>&gt;10</td>
</tr>
<tr>
<td>CAP45_G3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.0008</td>
<td>0.01</td>
</tr>
<tr>
<td>N156A</td>
<td>-</td>
<td>+</td>
<td>2E-05</td>
<td>3.9E-05</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>-</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Du156_12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.0003</td>
<td>0.001</td>
</tr>
<tr>
<td>N156A</td>
<td>-</td>
<td>+</td>
<td>3.4E-05</td>
<td>0.008</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>+</td>
<td>0.01</td>
<td>0.06</td>
</tr>
<tr>
<td>ZM53_12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.006</td>
<td>0.06</td>
</tr>
<tr>
<td>N156A</td>
<td>-</td>
<td>+</td>
<td>8.0005</td>
<td>0.06</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>-</td>
<td>4.6</td>
<td>0.01</td>
</tr>
<tr>
<td>ZM109_4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.008</td>
<td>0.1</td>
</tr>
<tr>
<td>N156A</td>
<td>-</td>
<td>+</td>
<td>0.001</td>
<td>0.02</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>-</td>
<td>5.4</td>
<td>&gt;10</td>
</tr>
<tr>
<td>CAP210_E8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.0002</td>
<td>0.03</td>
</tr>
<tr>
<td>N156N</td>
<td>+</td>
<td>+</td>
<td>0.0001</td>
<td>0.007</td>
</tr>
<tr>
<td>N160A</td>
<td>+</td>
<td>-</td>
<td>0.00001</td>
<td>0.007</td>
</tr>
<tr>
<td>ZM233_6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>+</td>
<td>+</td>
<td>0.0009</td>
<td>0.01</td>
</tr>
<tr>
<td>N928-28</td>
<td>+</td>
<td>+</td>
<td>1.1</td>
<td>0.9</td>
</tr>
</tbody>
</table>

**IC$_{50}$ neutralization**

- **WT:** <0.0001
- **N156A:** 0.001
- **N160A:** 0.01
- **1.0:** 1
- **10:** 10
- **>10:** 10

---

Immunity 47, 524–537, September 19, 2017
we observed a similar sensitivity pattern as that of the WT CAP256.25 Ab, suggesting that the germline residues contribute in a limited way to neutralization through their interactions with the Env glycans. In contrast, the CDRH2 somatically mutated substituted Ab variants, particularly involving the H59A substitution, showed some very marked differences with N160 glycan-eliminated viruses from WT CAP256.25 Ab. Figure 3A illustrates considerable decreases or even complete loss of neutralizing activity in some cases (Figure 3A). For example, Figure 3B shows that WT CAP256.25 Ab neutralizes two representative viruses, CAP45_G3 and Du156_12, and their N160A and N156A variants but that the H59A variant Ab is far less effective against the N160A viruses. Far less dramatic effects are seen for the N156A virus, implying that interaction of the CDRH2 somatic mutated residues with the N156 glycan (the remaining key glycan in the absence of N160) is most important for the effects observed.

We also included in this analysis a CAP256 Ab lineage member, CAP256.12, that had accumulated somatic mutations comparable to the other CAP256 bnAb members, including the two glycan-specific CDRH2 somatic mutations, but failed to show broad reactivity to the viruses (an “off-track Ab” in the nomenclature of Bhiman et al., 2015). The results revealed that the CAP256.12 Ab could efficiently neutralize certain isolates only when the glycan at position N160 was eliminated, suggesting that this Ab may have failed to accommodate or affinity mature with respect to the N160 glycan (Figure 3A).

Overall, the results demonstrate that both the germline and somatic mutated CDRH2 key heavy chain residues contribute to neutralization by CAP256.25 and PG16 but that somatically mutated residues are likely most important. Further, N156 may harbor the interacting sialic acids.

**N156 Glycans May Bear the Terminal Sialic Acids that Contact the Key Heavy Chain Residues on CAP256 and PG9 Family Antibodies**

We wished to obtain further evidence for the glycan or glycans that bear the sialic acid targeted by CAP256 Abs. We incorporated substitutions on the CRF250 SOSIP backbone to individually eliminate each of the four V1V2 apex glycans (N135, N141, N156, and N160) in turn, reasoning that treatment with 2,6-sialidase and comparison to the effect on WT trimer might reveal which of the glycans was most likely to harbor the critical sialic acid(s) (Figure 4A). Due to the inability of PGT145 Ab to bind N160 glycan-eliminated trimers (Andrabi et al., 2015), we chose 2G12 Ab to purify the WT CRF250 trimer and its single glycan variants prior to 2,6-sialidase treatment. Octet was used to investigate the binding of a selection of CAP256 mAbs to the glycovariants untreated or treated with 2,6-sialidase.

The effects of sialidase treatment were particularly marked for mAb CAP256.21, producing generally greatly reduced binding. The N156A variant showed lower binding overall and a lesser effect of sialidase treatment, implying that this Ab is dependent upon a sialic acid at N156. Of note, CAP256.21 Ab bound the N160A variant trimer with a higher affinity than even the WT CRF250 trimer, presumably involving an increased dependence on the N156 glycan in the absence of the N160 glycan (Figure 4B). However, upon 2,6-sialidase treatment, binding of CAP256.21 was dramatically lost, indicating that the sialic acid-specific interaction of this Ab at least is mediated through the N156 glycan. The binding of CAP256.25 bnAb to WT CRF250 trimer and glycan-modified variants showed reduced binding responses upon 2,6-sialidase treatment, except for the N156A variant, to which the relatively low binding response remained largely unchanged upon desialylation (Figures 4B and S4B). Overall, for WT, N135A, and N141A CRF250 trimer variants, the effects of sialidase were modest for most Abs (Figures S4A and S4B). For the N160A variant, the effects of sialidase were somewhat greater (Figures S4A and S4B). Therefore, although the earlier data provide evidence as to the interaction of CAP256 Abs with sialic acid, the glycan elimination studies here suggest possible involvement of N156 but they do not unambiguously determine the glycan involved.

In earlier studies, structural analysis of the PG16 Ab with a V1V2 scaffold showed that the terminal sialic acid residue at glycan N173 makes one and two hydrogen bonds with the CDRH2 germline-encoded residue K57 and the somatically mutated residue H59, respectively, in addition to three hydrogen bonds with PG16 Ab light chain residues (Figure 4C; Pancera et al., 2013). Of note, however, the PG16 Ab showed an enrichment of only 2% of the total ZM109F V1V2 on scaffold that possessed the appropriate glycoforms, suggesting an inherent glycan heterogeneity at this site and a strong preference of PG16 to bind 2,6-linked sialic acid-containing glycoforms. Recent studies using chromatography coupled mass spectrometry analysis of soluble Env proteins suggested that the N156 glycan position is occupied largely by a high-mannose glycan (Behrens et al., 2016; Panico et al., 2016). Another study (Cao et al., 2017) indicated that N156 is occupied either by high-mannose or high-mannose with some proportion of complex glycans for several soluble SOSIP.664 trimers, including the CRF250 trimer used in this study. Further studies are required to fully understand the compositions of the glycans in the V2 apex region on different isolates and expressed from different cell types. It should also be noted that only a sub-population of N156 or N173 glycan may be sialylated but this may be sufficient to drive sialic acid-specific affinity maturation in two independent V2 apex bnAb lineages.

Altogether, these results are consistent with the importance of a sialic acid residue, possibly on the glycan N156 or N173 at the V2 apex site, in driving the affinity maturation of the CDRH2 residues, Y59 to H and K64 to W, in CAP256 and PG9 V2 apex bnAb prototypes.

**Improved Sialic Acid Binding Is Associated with Development of bnAbs; Failure to Mature Such Binding Leads to Non-bnAbs**

To gain a better understanding of the importance of sialic acid recognition and the Ab mutations described above on bnAb development, we assessed the effects of sialidase treatment of CRF250 trimer on binding by the complete set of CAP256 Abs. We ranked the set of Abs according to the percentage change in octet binding (Figures 5A and 5B). The CAP256 Abs that displayed the most significant loss of binding (red color) upon removal of 2,6-linked sialic acid (CAP256.21, CAP256.30, CAP256.31, CAP256.12, and CAP256.13) had either the germ-line CDRH2 residue, D53, mutated to E or had both CDRH2 germline residues D53 and K57 mutated to A and Y, respectively (Figures 5A and 5B). All five of these Abs became “off target” Abs, suggesting that an “over-dependence” on sialic acid might
be detrimental to the development of neutralization breadth. In contrast, CAP256 Ab members that retained the germline residues Y59 and K64, or mutated at these positions to residues other than H at 59 and W at 64, generally showed enhanced binding to the α2,6-linked sialic acid-trimmed CRF250 trimer (Figures 5A and 5B, yellow in 5B). Thus, the unmutated ancestor version of CAP256 Abs may actually bind better to trimers lacking sialic acid.

In the middle part of Figure 5A (light red) are Abs that showed very modest changes upon removal of α2,6-linked sialic acid. These Abs typically have D53-K57-H59-W64 and show the greatest breadth of neutralization. For example, the broadest neutralizing Ab member, CAP256.25, exhibited very modest dependence on the α2,6-linked sialic acid. Thus, the data suggest that it may be vital for a developing bnAb to initiate sialic acid recognition but then keep a fine balance and not become

Figure 4. Binding of Select CAP256 Abs to CRF250 Trimer V2 Apex Glycan Variants Shows Varying Sensitivity to α2,6-Sialidase Treatment
(A) Schematic representation of the V2 apex individual glycan substituted variants on CRF250 SOSIP.664 trimer backbone.
(B) Octet binding curves (association: 120 s [180–300] and dissociation: 240 s [300–540]) of CAP256.21 and CAP256.25 Abs with CRF250 trimer glycovariants. The binding response of CAP256.25 bnAb with the CRF250 N156A variant is fixed to 0.2 nanometer (nm) for clarity.
(C) Ribbon representation of PG16 antibody (green) in complex with isolate ZM109F V1V2 loop (cyan) on a scaffold (modified from Pancera et al., 2013). The glycans at N160 (orange; shown as lines) and N173 (magenta; shown as lines) positions and the sialic acid residue (SIA; red) are labeled. The PG16 heavy chain CDRH2 residues (D53, K57, H59, and W64) are highlighted (blue). The residues K57 and H59 of the PG16 heavy chain show hydrogen bonding (yellow dotted line) with a terminal sialic acid residue of N173 glycan.
See also Figure S4.
over focused on sialic acid. Subsequently, this ability of the most mature CAP256 bnAb members to recognize a broad diversity of features within the V2 apex epitope, including a reduced dependence on sialic acid-bearing glycans, may increase their effectiveness against a wide range of viruses. The bnAbs may not only neutralize viruses with more varied protein epitopes but also tolerate glycoform heterogeneity at this site.

To further examine whether the sialic acid-specific affinity maturation of the glycan-specific CAP256 Ab sub-lineage was beneficial for the overall development of broad and potent Ab sub-lineage members, we analyzed next-generation sequencing (NGS) data of B cell transcripts from the CAP256 donor reported previously (Doria-Rose et al., 2014, 2015). The phylogenetic tree showed a strong bias toward the development of CAP256 Ab sub-lineage members that had accumulated sialic acid-specific CDRH2 somatic mutations (Figure 5C).

Overall, these results suggest that affinity maturation in a subset of CAP256 Ab lineage members to improve sialic acid binding provides them with a selective advantage in the progression toward a bnAb phenotype. Another subset of lineage members becomes over-dependent on sialic acid binding, loses some interaction flexibility, and shows moderate neutralization breadth. A third subset fails to acquire the crucial mutations to effectively interact with sialic acid and shows little or no breadth of neutralization.

Figure 5. Binding of the Full-Range of CAP256 Lineage Abs to CRF250 SOSIP.664 Shows a Gradation of Sensitivity to α2,6-Sialidase Treatment Dependent upon Key HCDR2 Residues

(A) Octet binding of CAP256-derived mAbs to PGT145 Ab affinity-purified CRF250 SOSIP.664 trimer (WT) and α2,6-desialylated version. The CAP256 mAbs were captured on an anti-human IgG-Fc sensor and then the CRF250 trimer forms (100 nM) flowed over. The binding response (nanometers [nm]) to WT and the α2,6-desialylated trimers is shown as color-coded numerical values and the CAP256 mAbs are arranged with respect to their binding sensitivity to α2,6-desialylated CRF250 trimer. The amino acids at four positions in the CDRH2 (with respect to germline positions D53, K57, Y59, and K64) are indicated for each Ab.

(B) Percent (%) change in the octet binding responses are shown as heatmap for the desialylated trimer form and is calculated as (Ab binding response to the α2,6-desialylated CRF250 trimer) / (binding response to the CRF250 WT trimer).

(C) Phylogenetic tree showing the development of the CAP256 bnAb lineage from the VH3-30*18 germline gene. The branches in the tree are color-coded and demonstrate the evolution of amino acid residues at the above-mentioned four positions in CDRH2. The germline residues (DKYK) and the most evolved residues (DKHW) in glycan-reactive Abs are indicated in green and red, respectively.

See also Figure S2C.
Maturation of CAP256 Antibodies to Bind Glycans Counters Viral Escape Occurring through Protein Sequence Variation and Promotes bnAb Development

Glycan-specific maturation is advantageous for the overall development of the CAP256 Ab lineage. Next, we sought to examine whether glycan recognition provided a means to counter virus escape. We generated virus mutants in CRF250 Envs at positions R166 (R166 to K, T, and S) and K169 (K169 to R, Q, and E) to mimic the virus escape mutations that occur naturally in the CAP256 donor (Bhiman et al., 2015; Doria-Rose et al., 2014). We then tested these CRF250 virus mutants against the entire panel of CAP256 Abs by neutralization. Strikingly, only Abs with somatic mutations in the CDRH2 region (Y59H and K64W) associated with sialic acid binding tolerated the R166T escape mutation (Figures 6A, 6B, and S5A). The same result was found for K169 escape mutations with the exception of CAP256.19 and CAP256.32, which tolerated K169Q escape mutations (Figures 6B and S5A). These observations suggest that the glycan-specific Ab mutations may provide a selection advantage to the CAP256 sub-lineage members to cope with viral escape occurring via mutation of strand C residues during infection.

To further investigate, we tested the ability of CDRH2 residue-substituted Ab variants on the background of CAP256.25 to neutralize apex bnAb putative escape variants of CRF250 (Figures 6C and S5B). As earlier, the CAP256.25 Ab Ala-substituted variants are less effective, by up to >1,000-fold, in terms of neutralization than WT Ab. However, the CDRH2 substitutions (H59A and W64A) eliminated neutralization of both R166K and K169Q CRF250 virus variants and reduced neutralization of the K169R virus mutant, under conditions for which the WT Ab is still neutralizing. These observations are consistent with the notion that the CDRH2 somatic mutations may help to counter neutralization escape via mutation in the V2 protein region.

Next, we investigated the binding of CAP256.25 WT Ab and variants to CRF250 WT Env trimer and putative escape variant Envs on the surface of 293T cells by flow cytometry. CAP256.25 WT Ab and variants bound strongly to CRF250 WT Env trimer. The WT Ab and variants exhibited significant binding to Env trimer from escape variants (R166 to T or S and K169E) that were not neutralized by the corresponding Abs (Figures 6D and S5C). The data suggest that the Env strand C residue mutations lead to the loss of neutralization at the Ab concentrations measured but trimer binding can still be detected (Figure 6D).

However, the CAP256.25 CDRH2 somatic mutation-substituted Ab variants completely lost binding to the surface-expressed Env trimer variants R166T, R166S, and R166S-K169E, thus specifically confirming their role in recognizing Env trimer sugars when the virus escapes. The data illustrate that the CDRH2 sialic acid-specific somatic mutations contribute to CAP256 bnAb binding to conserved glycans and may anchor the Abs to the virus as it tries to escape through changes in the protein sequence. Altogether, these results suggest that glycan-specific maturation of the CAP256 V2 apex bnAb lineages provides a means to counter virus escape and this in turn helps the Ab lineage to maintain a course toward bnAb development. The proposed B cell and virus co-evolutionary pathways that lead to the generation of CAP256 and PG9 V2 apex bnAb responses are then summarized in Figure S6.

DISCUSSION

Understanding the molecular events of bnAb developmental pathways during natural infection can provide valuable information for HIV vaccine design (Bonsignori et al., 2017). Recent Ab-virus co-evolution studies have led to a better understanding of the complex molecular events that give rise to the CAP256 bnAb lineage recognizing the V2 apex of the Env spike (Bhiman et al., 2015; Doria-Rose et al., 2014, 2015). This Ab lineage was triggered by the superinfecting virus Env sequence, or a close descendant, that showed significant binding to the unmutated common ancestor (UCA) Ab. Viral envelope diversification around the strand C residues in the V2 loop was coincident with broadening of the neutralization by CAP256 Abs against diverse isolates. However, it was largely unclear how the Ab genetic determinants, either germline-encoded or acquired during affinity maturation, maintain interaction with a constantly diversifying virus, to keep the Ab lineage on a bnAb developmental pathway. Here we carried out a series of experiments to better understand the critical Ab determinants and their role in the evolution of bnAbs.

We noted earlier that CAP256.09 and PG9 V2 apex bnAb precursors possess germline-encoded motifs in their CDRH3 and CDRH2 that interact with the V2 protein and glycan core epitope, allowing them to bind to some native Env trimers in their unmutated ancestor Ab configurations. This property of V2 apex bnAbs provides an opportunity to base B cell precursor-targeting priming immunogens on native-like trimer conformation rather than designed non-native structures, and thereby to potentially restrict the initial Ab angle of approach to more native-like conformations.

Here, we observed a conserved pattern of sialic acid binding affinity maturation in the CDRH2 region of two genetically related independent Ab lineages. The somatic mutations appeared to facilitate recognition of a terminal sialic acid, possibly on the N156 glycan at the apex of the Env trimer. Phylogenetic analysis revealed the selective development of CAP256 Ab sub-lineage members that bore these glycan-specific somatic mutations. These mutations likely helped the CAP256 Ab sub-lineage members to firmly bind to the Env glycans in germinal centers to compete with the non-glycan reactive Ab sub-lineage members, thus giving them a selective advantage (Figure S6). Although the accumulation of CDRH2 glycan-specific somatic mutations increased the likelihood of CAP256 Ab lineage members progressing to bnAbs, additional affinity maturation to accommodate or recognize the adjacent N160 glycan appeared to be important to acquire a bnAb phenotype.

Another important factor on the pathway to bnAbs appears to be virus diversification around the V2 apex core epitope (Bhiman et al., 2015). Indeed, a number of recent studies have shown that the viral diversification through escape generates a range of immunotypes that drive virus-Ab co-evolution pathways to expand Ab virus coverage (Bhiman et al., 2015; Doria-Rose et al., 2014; Liao et al., 2013; Moore et al., 2012; Wibmer et al., 2013). Presumably, only a subset of Ab sub-lineage members that tolerate the virus escape mutations can keep affinity maturing. Indeed, our results revealed that by virtue of recognizing a conserved glycan on Env through germline-encoded and early glycan-specific somatic mutations, the CAP256 Ab sub-lineage members
Figure 6. Sialic Acid-Binding Residues on CAP256.25 bnAb Are Critical in Resisting Virus Escape via Mutations in the Basic Residue-Rich Region of V2

(A) Phylogenetic tree constructed from VH sequences displaying members of the CAP256 bnAb lineage evolved from the VH3-30*18 germline gene.

(B) Neutralization heatmap based on the IC_{50} neutralization titers of CAP256 Ab lineage members with CRF250 WT virus and its 166 and 169 position (HXB2 numbering)-substituted variants that represent escape mutations of CAP256 Abs in natural infection (Bhiman et al., 2015). The four CDRH2 amino acid positions, important for glycan recognition, are shown for each Ab member. The lineage members that possess an H and W amino acid residues at positions 59 and 64, respectively, are highlighted in red.

(C) Neutralization heatmap of CAP256.25 Ab and its CDRH2 variants against CRF250 WT virus and positions 166- and 169-substituted variant viruses.

(D) Binding of CAP256.25 WT Ab and variants to 293T cell-surface expressed CRF250 WT Env and putative escape variant Env trimers. The Abs were used at a final concentration of 10 μg/mL and the extent of binding to the surface trimers is represented as % positive cells as detected by PE-conjugated anti-human-Fc secondary Ab. The V3-N332 high-mannose glycan-specific Ab PGT128, the gp120-41 trimer cleavage-specific Ab PGT151, and a non-HIV Env epitope-specific Ab DEN3 were controls for the assay.

See also Figures S5 and S6.
maintain a cognate interaction with the would-be escaping virus. In other words, CAP256 and PG9 V2 apex bnAb recognition of the Env glycans allows Ab evolution toward bnAbs as virus attempts to escape. It will be of interest to see whether glycan-reactive bnAbs that target other HIV Env specificities use a similar strategy to counter virus escape.

A further point of interest is that the sialic acid-binding somatic mutations observed in the CDRH2 region occur proximal to the sialic acid-binding germline residues and the patterns described could potentially be used as signatures to track the developmental pathways of Ab lineage in a vaccine response aimed at inducing the PG9 or CAP256-like V2 apex bnAbs.

Finally, our study provides a germane example of how a human mAb longitudinally develops interaction with a pathogen-associated glycan, which endows it with the ability to better cope with escape in the protein part of the Ab epitope. It also highlights the need for immunogens to include authentic glycan compositions to maximize the chances of inducing bnAbs. The data will help in our efforts to design HIV immunogens with better precision and in optimizing immunization strategies to induce V2 apex bnAb responses.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Cell lines
- **METHOD DETAILS**
  - Antibodies, expression and purification
  - Site directed mutagenesis
  - Pseudovirus production
  - Neutralization assay
  - Recombinant envelope protein expression and purification
  - Glycan Microarray
  - Sialidase treatment of purified CRF250 trimer protein
  - Phylogenetic analysis of CAP256 bnAbs
  - Cell surface binding assay

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and can be found with this article online at http://dx.doi.org/10.1016/j.immuni.2017.08.006.

AUTHOR CONTRIBUTIONS


ACKNOWLEDGMENTS

We thank John R. Mascola and Nicole A. Doria-Rose for providing CAP256.08 and CAP256.09 antibodies. We thank James C. Paulson for critical comments on the manuscript and Lars Hangartner, Lynn Morris, Penny Moore, and Jinal N. Bhiman for useful discussions. This work was supported by the International AIDS Vaccine Initiative (IAVI) through Neutralizing Antibody Consortium SFP1849 (D.R.B.); the National Institute of Allergy and Infectious Diseases (Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery Grant UM1AI100663 to D.R.B.); and the Ragon Institute of MGH, MIT, and Harvard (D.R.B.). This study was made possible by the generous support of the Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD) and the American people through USAID. We thank Christina Corbaci and for her help in the preparation of figures.

Received: February 27, 2017
Revised: June 5, 2017
Accepted: August 16, 2017
Published: September 12, 2017

REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse Anti-Human IgG Fc-PE</td>
<td>SouthernBiotech</td>
<td>Cat# 9040-09</td>
</tr>
<tr>
<td>R-Phycocerythrin AffiniPure Goat Anti-Human IgG, Fc Fragment Specific</td>
<td>Jackson Immuno Research Inc.</td>
<td>Cat# 109-115-098</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>293fectin</td>
<td>Invitrogen</td>
<td>Cat# 12347500</td>
</tr>
<tr>
<td>X-tremeGENE 9 DNA Transfection Reagent</td>
<td>Sigma-Aldrich</td>
<td>Cat# 6365809001</td>
</tr>
<tr>
<td>PEI MAX 40000</td>
<td>Polysciences, Inc.</td>
<td>Cat# 24765-1</td>
</tr>
<tr>
<td>Kifunensine</td>
<td>TOCRIS</td>
<td>Cat# AL-3207</td>
</tr>
<tr>
<td>Swainsonine</td>
<td>Cayman</td>
<td>CAS# 72741-87-8</td>
</tr>
<tr>
<td>α2,3 sialidase</td>
<td>Sigma-Aldrich</td>
<td>Cat# N7271</td>
</tr>
<tr>
<td>α2,6 sialidase</td>
<td>Sigma-Aldrich</td>
<td>Cat# N3786</td>
</tr>
<tr>
<td>α2,8 sialidase</td>
<td>Sigma-Aldrich</td>
<td>Cat# N2876</td>
</tr>
<tr>
<td>α2,9 sialidase</td>
<td>Sigma-Aldrich</td>
<td>Cat# N8271</td>
</tr>
<tr>
<td>CRF250 SOSIP.664</td>
<td>Andrabi et al., 2015</td>
<td>N/A</td>
</tr>
<tr>
<td>BG505 SOSIP.664</td>
<td>Sanders et al., 2013</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QuickChange II XL Site-Directed Mutagenesis Kit</td>
<td>Agilent Technologies</td>
<td>Cat# 200522</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEK293T</td>
<td>ATCC</td>
<td>Cat# CRL-3216</td>
</tr>
<tr>
<td>FreeStyle 293-F</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# R79007</td>
</tr>
<tr>
<td>HEK293S GnT1-</td>
<td>ATCC</td>
<td>Cat# CRL-3022</td>
</tr>
<tr>
<td>TZM-bl</td>
<td>NIH AIDS Reagent Program</td>
<td>Cat# 8129</td>
</tr>
<tr>
<td><strong>Recombinant DNA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pSG3Denv plasmid</td>
<td>NIH AIDS Reagent Program</td>
<td>Cat# 11051</td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prism v7.0</td>
<td>GraphPad</td>
<td><a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a></td>
</tr>
<tr>
<td>GenePix Pro 6.0</td>
<td>Molecular Devices</td>
<td><a href="http://mdc.custhelp.com/app/answers/detail/a_id/18691/~/genepix-6-pro-6-microarray-acquisition">http://mdc.custhelp.com/app/answers/detail/a_id/18691/~/genepix-6-pro-6-microarray-acquisition</a></td>
</tr>
<tr>
<td>ForteBio Data Analysis v.9</td>
<td>ForteBio</td>
<td><a href="http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/">http://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/</a></td>
</tr>
<tr>
<td>AbStar</td>
<td>N/A</td>
<td><a href="https://github.com/briney/abstar">https://github.com/briney/abstar</a></td>
</tr>
<tr>
<td>Clonify</td>
<td>N/A</td>
<td><a href="https://github.com/briney/clonify-python">https://github.com/briney/clonify-python</a></td>
</tr>
<tr>
<td>CD-HIT</td>
<td>N/A</td>
<td><a href="http://weizhongli-lab.org/cd-hit/">http://weizhongli-lab.org/cd-hit/</a></td>
</tr>
<tr>
<td>MUSCLE</td>
<td>N/A</td>
<td><a href="http://www.ebi.ac.uk/Tools/msa/muscle/">http://www.ebi.ac.uk/Tools/msa/muscle/</a></td>
</tr>
<tr>
<td>FastTree</td>
<td>N/A</td>
<td><a href="http://www.microbesonline.org/fasttree/">http://www.microbesonline.org/fasttree/</a></td>
</tr>
<tr>
<td>ETE Toolkit</td>
<td>N/A</td>
<td><a href="http://etetoolkit.org">http://etetoolkit.org</a></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-human IgG Fc Capture (AHC) Biosensors</td>
<td>ForteBio</td>
<td>Cat#18-5060</td>
</tr>
<tr>
<td>Superdex 200 Increase 10/300 GL column</td>
<td>GE Healthcare</td>
<td>Cat# 28990944</td>
</tr>
</tbody>
</table>

### CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by Dennis R. Burton (burton@scripps.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines
Human Embryonic Kidney (HEK293T) cell line is a highly transfectable version of 293 human embryonic kidney cells that contain SV40 T-antigen. The FreeStyle 293-F cell line is derived from the 293 cells that are adapted to suspension culture in FreeStyle 293 Expression Medium. HEK293S GnT- cells are human embryonic kidney cells that are transformed with adenovirus 5 DNA. These cells lack N-acetyl-glucosaminyltransferase I (GnTI) activity and are therefore unable to produce complex-type N-glycans. TZM-bl is a HeLa cell line that expresses CD4 receptor and CXCR4 and CCR5 chemokine co-receptors. The cell line also expresses luciferase and β-galactosidase genes under the control of the HIV-1 promoter, hence is useful to assay in-vitro HIV infection.

METHOD DETAILS

Antibodies, expression and purification
V2 apex bnAb prototypes, PG9 (PG9, PG16), CAP256.09 (CAP256.01-CAP256.32 and CAP25611-12, CAP256 UCA) described previously were included in this study (Doria-Rose et al., 2014; Walker et al., 2009). A trimer-specific V2 apex bnAb, PGT145, and a V2 apex bnAb prototypes, PG9 (PG9, PG16), CAP256.09 (CAP256.01-CAP256.32 and CAP25611-12, CAP256 UCA) described elsewhere were used as control Abs for various experiments (Falkowska et al., 2014; Walker et al., 2011). For antibody production, the heavy and light chain encoding plasmids were reconstituted (1:1 ratio) in Opti-MEM (Life Technologies), and cotransfected into Human Embryonic Kidney 293 FreeStyle cells (HEK293F cells) (Invitrogen) using 293fectin (Invitrogen). The suspension cells were cultured for 4-5 days in a shaker incubator at 8% CO2, 37.0°C, and 125 rpm. The antibody containing supernatants were harvested, filtered through a 0.22 mm Steriflip units (EMD Millipore) and passed over a protein A or protein G affinity column (GE Healthcare). The bound antibody was eluted from the columns in 0.1 M citric acid, pH 3.0. Column fractions containing IgG were neutralized (2M Tris-base), pooled, and dialyzed against phosphate-buffered saline (PBS), pH 7.4. IgG purity was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the concentration was determined by measuring the relative absorbance at 280 nm.

Site directed mutagenesis
The amino acid point mutations in the antibody encoding plasmids and the HIV envelope plasmids were incorporated by using a QuikChange site-directed mutagenesis kit (Agilent Technologies, USA), according to the manufacturer’s instructions. All the mutations were confirmed by DNA sequence analysis (Eton Bioscience, San Diego, CA).

Pseudovirus production
To produce pseudoviruses, env-encoding plasmids were cotransfected with an env-deficient backbone plasmid (pSG3Δenv) (1:2 ratio) using X-tremeGENE 9 (Sigma-Aldrich) DNA transfection reagent. Briefly, 1X10⁶ cells in 10ml of Dulbecco’s Modified Eagle Medium (DMEM) were seeded in a 100mm x 20mm cell culture dish (Corning) one day prior to transfection. For transfection, 40μl of X-tremeGENE 9 was added to 700μl of Opti-MEM I reduced serum medium (Thermo Fisher) in tube 1. The env-encoding plasmid (5 μg) and pSG3Δenv (10 μg) were added to tube 2 in 700μl of Opti-MEM. The tube 1 and tube 2 solutions were mixed together and incubated for 25 min at room temperature. Next, the transfection mixture was added to the media with 293T cells seeded previously and then distributed uniformly. To produce glycan-modified pseudovirus variants (Glycovariants: (GVT)) of CRF250 env, we added the α-mannosidase I and II inhibitors, kifunensine (Tocris) and swainsonine (Cayman) respectively, at a final concentration of 25 μM, to the 293T cells on the day of transfection. All pseudoviruses were harvested 48-72 h posttransfection, filtered through 0.22 mm Steriflip units (EMD Millipore) and aliquoted for use in neutralization assays.

Neutralization assay
Neutralization was measured by using single-round replication-defective HIV env-pseudoviruses and TZM-bl target cells (Montefiori, 2005; Seaman et al., 2010). 25ul of 3-fold serially diluted mAbs were pre-incubated at 37°C for 1h with 25ul of tissue culture infective dose-50 (TCID50) env-pseudotyped virus in a half-area 96-well tissue culture plate. TZM-bl target cells (5,000 cells/well) in 50ul of DMEM were added and the plates were allowed to grow in humidified incubator at 37°C and 5% CO2. The luciferase activity of the lysed cells was read on instrument (Biotek) after 2-3 days, by adding lysis buffer followed by Brightglow (Promega). The 50% inhibitory concentration (IC₅₀) was reported as the antibody concentration required to reduce infection by half.

Recombinant envelope protein expression and purification
Recombinant envelope proteins were expressed in HEK293F or HEK293S cells as described elsewhere (Sanders et al., 2013). Briefly, the CRF250 SOSIP.664 or BG505 SOSIP.664 encoding plasmids was cotransfected, with a plasmid encoding for Furin (3:1 ratio) specific for R6-cleavage site (RRRRRR), into HEK293F cells using PEI-MAX 4000 transfection reagent (Polysciences, Inc.). To produce the CRF250 SOSIP.664 trimer proteins with varying glycan composition, the glycosidase inhibitors kifunensine and swainsonine were added to the HEK293F cell cultures at a final concentration of 25 μM at the time of transfection (Doores and Burton, 2010). The CRF250 SOSIP.664 was grown in GnT1-deficient (GnT1−/−) HEK293S cells to produce a Man₅₋₆GlcNAc₂ glycan containing trimer. The CRF250 SOSIP.664 gp140 WT and glycovariant trimers were purified from supernatants using a 2G12 Ab antibody affinity
column while BG505 trimer and CRF250 WT trimer used for other experiments were purified with a bnAb PGT145 affinity column as described previously (Pugach et al., 2015; Sanders et al., 2013). The affinity-purified proteins were size exclusion chromatography (SEC)-purified with a Superdex 200 10/300 GL column (GE Healthcare) in PBS.

Bio Layer Interferometry (BLI) binding assay

The binding experiments of Abs to WT and glycan modified purified trimers were performed with an Octet K2 system (ForteBio, Pall Life Sciences). Briefly, the mAbs or IgGs (10 μg/mL in PBST) were immobilizing onto hydrated anti-human IgG-Fc biosensors (AHC: ForteBio) for 60 s to achieve a binding response of at least 1.0. After Ab capture, the sensor was placed in a PBST wash buffer to remove the unbound Ab to establish a baseline signal. Next, the IgG immobilized sensor was dipped into a solution containing SOSIP.664 trimer protein as analyte and incubated for 120 s at 1000 rpm. Following this, the trimer bound to IgG immobilized sensor was removed from the analyte solution and placed into the PBST buffer for 240 s at 1000 rpm. The 2 and 4 min binding intervals respectively denote the association and dissociation binding curves reported in this study. The sensograms were corrected with the blank reference and fit (1:1 binding kinetics model) with the ForteBio Data Analysis version.9 software using the global fitting function. The data is represented as maximum binding response or the association and dissociation curve fits.

Glycan Microarray

Abs were assessed for glycan reactivity with amine functional glycans printed onto NHS-activated glass slides as previously described (Shivatare et al., 2016). Briefly, amine-functionalized glycans were printed in replicates of three onto NHS-activated glass slides at a concentration of 100 mM. Printed slides were allowed to react in an atmosphere of 80% humidity for 2 hour followed by desiccation overnight, and stored at room temperature in a desiccator until use. The slides were blocked with ethanolamine (50mM in borate buffer, pH9.2) just before use. Monoclonal antibodies (10 μg in 50μl PBS) were pre-complexed with R-Phycocerythrin-AffiniPure goat anti-human IgG, Fcγ (5 μg, Jackson Immuno Research Inc.) for 1 hr at 4°C. These samples were added to the glycan array and incubated at 4°C for 4 h. Further, the slides were sequentially washed in PBST (0.05% Tween-20), PBS and water. Arrays were scanned on an ArrayWorx microarray reader. Image analysis was carried out with Genepix Pro 6.0 analysis software (Molecular Devices Corporation, Union City, CA) with image resolution set to 5 μm per pixel. The spots were defined as circular features with maximum diameter of 100 μm. The data was recoded as fluorescence intensity (a.u.) for all data points and is represented as average fluorescent intensity with standard deviation.

Sialidase treatment of purified CRF250 trimer protein

To study the role of terminal sialic acid residues in the binding of CAP256.09 and PG9 Ab prototypes, we treated PGT145 purified CRF250 trimer with sialidases or neuraminidases to linkage-specifically remove sialic acid residues following methods described previously (Lin et al., 2015; Wang et al., 2009). First, the CRF250 trimer sample was buffer exchanged to replace with the buffer system optimal for sialidase reaction. The trimer sample was treated with various sialidases from 0.5 to 8 hr at 37°C that show different specificities for the linkage between galactose and the terminal sialic acid. These include, α,2,3 sialidase from Streptococcus pneumonia (Sigma, N7271), which hydrolyzes non-reducing terminal α,2,3-linked sialic acids from the glycans, sialidase A from Arthrobacter ureafaciens (Sigma, N3786) to release α,2,6-linked sialic acids. The trimer sample was also treated with a mixture of four sialidases (α,2,3,6,8,9) (Sigma, N7271/N3786/N2876/N8271) to remove α,2,3, α,2,6, α,2,8, and α,2,9-linked sialic acid from glycans.

Phylogenetic analysis of CAP256 bnAbs

Sequencing data previously obtained from donor CAP256 was downloaded from the NIH Short Read Archive and annotated with AbStar. Lineages were assigned with Clonify (Briney et al., 2016b) and the CAP256 bnAb lineage was identified using homology to all CAP256 derived mAb heavy chains. All NGS sequences in the CAP256 lineage were clustered at 97.5% identity with CD-HIT (Li and Godzik, 2006), and centroid sequences for each cluster were used to construct the phylogenetic tree. A multiple sequence alignment of NGS centroid sequences, bnAb sequences (CAP256.01-32), inferred intermediates (CAP256.I1 and I2) and the CAP256 UCA was calculated with MUSCLE (Edgar, 2004); a tree file was computed with FastTree (Price et al., 2010); and the phylogenetic tree was visualized in Python using the ETE toolkit (Huerta-Cepas et al., 2010).

Cell surface binding assay

Binding of mAbs to the HEK293T cell-surface expressed Env trimers was performed as described previously (Walker et al., 2009). Briefly, 5-fold serial dilutions of mAbs starting at 10 μg/ml were added to HEK293T cells 48-hours post-transfection with CRF250 WT and its R166 and K169 substituted Env trimer variant plasmids. The Abs were incubated with cells for 1 hr on ice on a plate rocker. The plates were washed twice in FACS buffer (1X PBS, 10% FBS) and stained with a 1:200 dilution of R-phycocerythin (PE)-conjugated mouse anti-human IgG1 Ab (SouthernBiotech). Ab binding to surface trimers was analyzed using flow cytometry (Accuri cytometers), and the binding curves were generated by plotting the percent (%) positive cells of antigen binding as a function of antibody concentration or % positive cells as bars, at the highest Ab concentration (10 μg/ml). PGT128, a high mannose V3-N332 Ab, PGT151, a trimer dependent gp120-41 cleavage-specific Ab and DEN3, an HIV Env unrelated Ab, were used as controls to monitor the expression of well-cleaved trimers on the cell-surface.
Supplemental Information

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development

Supplemental information

**Figure S1.** CAP256 mAbs showed varied neutralizing activity of CRF250 WT virus and its glycan eliminated variants and glycovariants. Related to Figure 1.

**A.** Neutralizing activity of CAP256 mAbs against CRF250 WT virus (293T cells), CRF250 glycan eliminated variants (N156A and N160A) and CRF250 virus glycovariants. The glycovariants are grown in 293T cells in the presence of glycoside inhibitors kifunensine (Kif: ER α - mannosidase I inhibitor) or swainsonine (Swain: Golgi α-mannosidase II inhibitor) or in 293S cells that lack an N-acetyl glucosaminyl transferase enzyme. The Abs were tested in a concentration range (0.00001-10 µg/ml) and the numerical values indicate IC50 neutralization titers using TZM-bl target cells. The information is color-coded with deep red colors indicating more potent neutralizing activity. The bnAbs PGT145 and PGT128 were used as controls.

**B-E.** Trends in glycan-dependent neutralization by CAP256 mAbs. **B.** Neutralization of CRF250 WT virus (grown in 293T cells) and two glycan eliminated virus variants (N156A and N160A). **C.** Neutralization of CRF250 WT virus or virus grown in the presence of glycoside inhibitors, kifunensine and swainsonine and the virus produced in 293S cells by CAP256 mAbs. **D.** Neutralization of CRF250 N156A virus grown in 293T cells alone or in combination with kifunensine or swainsonine by CAP256 mAbs E. As for (C) but for CRF250 N160A virus.
Figure S2. CAP256 mAb members display binding to α2,6 sialic acid bearing glycans on glycan microarrays and soluble HIV Env trimer protein. Related to Figure 1 and Figure 5.

A. The reactivity of CAP256 mAbs was assessed to a variety of glycan on glycan microarray and the data were recorded as fluorescence intensity (a.u.). The binding activity of mAbs is represented as average fluorescence intensity.

B. Types of glycans used in the assay and the symbols for individual monosaccharides units are shown.

C. Octet kinetics of CAP256 mAbs binding to WT CRF250 SOSIP.664 trimer and desialylated forms. Octet binding of CAP256 mAbs to CRF250 WT trimer and α2,3 or α2,6 or a combination of α2,3,6,8,9-sialidase-treated trimers to specifically cleave terminally linked sialic acid residues. MAbs at 10µg/ml
concentration were captured onto an anti-human IgG-Fc sensor (AHC: ForteBio.) to achieve binding of at least 1 response unit (1 RU). The IgG immobilized biosensor was immersed in the 100nM trimer solution with trimer as the analyte and the binding curves are shown indicating the association (120 s; 180-300) and dissociation (240 s; 300-540) of Ab-trimer interaction. The CAP256 mAbs that displayed binding to $\alpha$2,6 sialic acid-containing glycans on glycan microarray are shown in red.
Figure S3. Germline encoded and somatic mutated CDRH2 heavy chain residues are important for binding and neutralization of CRF250 Env glycovariants. Related to Figure 2.

A. Amino acid sequence alignment of the heavy chain variable regions of CAP256 mAbs with the unmutated common ancestor Ab (CAP256 UCA). The amino acid residues are labeled according to the Kabat numbering scheme. The antibody CDR and FR junctions are underlined and highlighted (yellow). The Ab lineage members that showed both reactivity to the α2,6 sialic acid-containing glycans on the glycan microarray and/or binding sensitivity to α2,6 sialidase treated CRF250 trimer are highlighted in red and include the broadest Ab member in this Ab family, CAP256.25 Ab. The remaining CAP256 Ab members did not show either binding to glycans on the glycan microarray or reduced binding to CRF250 trimer upon α2,6 sialidase treatment and are shown in black. Sequence analysis revealed 9 amino acid positions (CDRH2 = 4 and CDRH3 = 5) in the heavy chain variable region that could potentially differentiate glycan-reactive CAP256 Ab sub-lineage mAbs from non-glycan reactive mAbs. CAP256.04 and CAP256.26 mAbs were exceptions that shared sequence similarity with the glycan-reactive Ab members but failed to display either binding
to glycans on the array or show sensitivity to the α2,6 sialidase treated CRF250 trimer binding.

B. Neutralization of CRF250 virus and octet binding kinetics of CRF250 and BG505 SOSIP.664 soluble trimer proteins by CAP256.09 antibody (WT) and its 9 heavy chain single amino acid substituted Ab variants.

C-F. Neutralization of CRF250 glycovariant viruses and binding of CRF250 trimer glycovariants by CAP256.09, CAP256.25, PG9 and PG16 mAbs. C. Neutralization of CRF250 WT (293T) and glycan-modified viruses (293T + swainsonine and 293S cells) by CAP256.09 WT Ab and 9 variants and D. Octet binding kinetics of 2G12 Ab-purified soluble SOSIP.664 trimer glycovariants for CAP256.09 WT Ab and the 9 variants. The CRF250 glycovariant viruses and trimers were grown either in the presence of Golgi α-mannosidase II inhibitor swainsonine (Swain; at 25 µM final concentration) or in 293S cells that lack N-acetyl glucosaminyl transferase enzyme. The neutralization IC50 values for the WT CRF250 virus and its two glycovariants are denoted by rectangles just above the X-axis (293T = blue, 293T + Swain = green and 293S = orange) and show the change in neutralization capacity of each Ab variant. E. Fold change in neutralization IC50 for CAP256.09 and the 9 Ab variants for 293T + swain and 293S grown CRF250 virus compared to the 293T grown virus. A small decrease in neutralizing ability for the W64A CDRH2 Ab variant and increase for two of the CDRH3 variants (D99A and W100E-A) against the swainsonine-treated virus as compared to the WT CAP256.09 Ab is noted. The neutralizing ability of all the four CDRH2 Ab variants (D53A, K57A, H59A and W64A) increased substantially for 293S cell grown CRF250 virus, indicating that the substitution of these germline and somatic mutated residue with alanine leads to enhanced interaction with Env trimer with smaller high mannose glycan (lacking complex-type glycans). F. The CAP256.25, PG9 and PG16 and their CDRH2 Ab mutants were tested for neutralization and octet binding of the CRF250 virus or SOSIP.664 trimer glycovariants. As for CAP256.09 Ab variants, the CAP256.25, PG9 and PG16 CDRH2 Ab variants showed improved binding to the 293S produced trimers when the glycan-specific Ab somatic mutations are removed.
Figure S4. Octet binding kinetics of the CAP256 mAbs to the WT CRF250 trimer and its V2 apex single glycan removed variants shows varied sensitivity to α2,6 sialidase treatment. Related to Figure 4.

A. Octet binding curves (association: 120 s; (180-300) and dissociation: 240 s; (300-540)) for CAP256 Abs with WT CRF250 trimer and its individual V2 apex
glycan eliminated variants (N135A, N141A, N156A and N160A), purified by 2G12 Ab affinity chromatography. Like the PGT145 Ab-purified WT CRF250 trimer and its desialylated form (Figure S4), the binding of CAP256 Abs generally showed a similar pattern of somewhat reduced binding to the $\alpha$2,6 desialylated form of 2G12 Ab-purified CRF250 WT trimer, indicating trimer populations enriched by both the Abs likely had comparable $\alpha$2,6 sialic acid-bearing glycoforms around the apex. The binding response of CAP256 mAbs with the CRF250 N156A glycan removed variant, which showed the most dramatic reduction in the binding, is fixed to 0.2 nanometer (nm) binding response for clarity. A High-mannose glycan specific Ab, PGT128, and a complex-type tri or tetra-antennary glycan specific Ab, PGT151 that only binds to the cleaved Env trimers, were used as controls. The binding response of PGT151 Ab with the N156A and N160A glycan eliminated trimer variants was reduced as compared to the WT CRF250 trimer suggesting the lack of these individual glycans may potentially affect trimer assembly.

**B.** Binding response, dissociation constants (KD), antibody on-rate (kon(1/Ms)) and off-rate (kdis(1/s)) or “koff” of the CAP256 mAbs with WT CRF250 SOSIP.664 trimer, its individual V2 apex glycan eliminated variants and their $\alpha$2,6 desialylated versions.
Figure S5. Sialic acid-binding HC residues of CAP256 mAbs are critical for neutralization and binding of CRF250 Env variants that mimic escape mutations in the CAP256 donor virus. Related to Figure 6.

A. Neutralizing activity of CAP256 mAbs against CRF250 WT virus and R166- and K169-variants corresponding to escape mutations in the CAP256 superinfecting virus (CAP256.SU: donor virus that led to the CAP256 Ab lineage). The IC50 neutralization titers for each Ab-virus combination are shown as numerical values with the intensity of red colors representing the Ab potency. The neutralizing activity of the control bnAbs, PGT128 and PGT151 remained largely unchanged with V2 apex Env substitutions.

B. The neutralizing activity of CAP256.25 WT Ab and its CDRH2 Ab variants against R166 and K169 substituted Env virus variants.

C. Flow cytometry binding of CAP256.25 Ab and its CDRH2 variants to cell-surface expressed CRF250 Env trimer variants. The CRF250 WT Env and its R166 and K169 V2 region-substituted variants were expressed on the surface of 293T cells as membrane-bound trimers. The CAP256.25 WT Abs and its CDRH2 Ab variants were evaluated for binding to Env trimer mutants using 5-fold titration decreasing concentration steps of Ab beginning at 10μg / ml. Binding was detected by a PE-conjugated anti-human-Fc secondary Ab and is represented as % positive cells. The Abs PGT128, PGT151 and DEN3 were controls for the assay. The PGT128 and PGT151 control Abs revealed that most of the Env trimer variants displayed comparable surface expression of well-cleaved trimers, except a relatively low expression level for two CRF250 Env K169 variants, K169R and K169Q.
Figure S6. Proposed virus and B-cell co-evolutionary pathways that lead to CAP256 and PG9 V2 apex bnAbs. Related to Figure 1-6.

The schema shows a proposal for how a V2 apex bnAb response may be generated in HIV natural infection. Upon initial infection, a viral envelope sequence that has affinity for the V2 apex bnAb germline precursors, presented as a trimeric protein spike on the HIV virion surface (grey sphere), is proposed to select and trigger an appropriate precursor B-cell expressing Ab with a long CDRH3 loop (Antibody; Y-shape). The CDRH3 loop (shown in cyan) rich in anionic residues incorporates a germline D-gene encoded motif (YYD) to interact with the lysine-rich region (K-rich: shown as green rectangle) of the V2 apex core epitope by penetrating between glycans N156 and N160 (shown as blue spheres). Germline-encoded CDRH2 residues D53 and K57 contact the α2,6 terminally linked sialic acid (shown as purple diamond) likely on the N156 Env glycan. The V2 apex bnAb precursors further accumulate two somatic mutations (SHM) in the adjacent CDRH2 residues, Y59H and K64W (represented as yellow triangle), which further strengthen the interaction with a terminal sialic acid (indicated in dotted line). The circulating virus initiates an escape pathway by mutating the positively charged residues in the strand C core epitope to loosen interaction with the CDRH3 anionic residues of the antibody. The germline B-cells that have not accumulated the CDRH2 somatic mutations lose cognate interaction with the escaping virus and this B-cell lineage terminates but the B-cells with additional sialic acid-specific somatic mutations are able to maintain interaction, albeit at lower affinity. These B cells can now accumulate further SHM in the antibody variable regions that allow V2 apex bnAbs to accommodate potential virus escape mutations in the strand-C K-rich region. Thus, Env glycan recognition by V2 apex bnAb precursors early in the antibody developmental pathway is proposed to help these Abs to tolerate potential escape mutations in
the protein part of the epitope and helps them to deal with the variations in the core epitope of escaping virus that enables them to broaden coverage across a range of diverse HIV isolates. Some Abs appear to mature towards enhanced sialic acid binding at the expense of broader recognition and become “off-target antibodies”.